Sermorelin | GHRH 1-29 Analogue

Research Overview

Sermorelin is a synthetic analogue of the first 29 amino acids of endogenous growth hormone releasing hormone (GHRH 1-29-NH2). It was previously FDA-approved as a diagnostic agent for GH deficiency before being discontinued for commercial reasons, and remains an active subject of research.

Research has examined Sermorelin’s mechanism of action through GHRH receptors in the pituitary gland, its role in stimulating endogenous GH synthesis and secretion, and its profile in animal models of GH axis research. Studies have compared its action to exogenous GH administration.

Select Published Research

Walker RF (2006). “Sermorelin: a better approach to management of adult-onset growth hormone insufficiency?” Clinical Interventions in Aging.
Vittone J et al. (1997). “Effects of single nightly injections of growth hormone-releasing hormone (GHRH 1-29) in healthy elderly men.” Metabolism.

All referenced studies were conducted in research settings. These citations do not constitute claims of safety or efficacy for unsupervised use.

Specifications

Format: Lyophilized powder
Purity: >99% verified by HPLC and mass spectrometry
Storage: −20°C lyophilized. Reconstituted: 4°C, use within 30 days.
Source: Domestically synthesized

Certificate of Analysis

Third-party COA available in the Lab Results tab above.